



Update on OCM review - listing notice for sodium fluoride
[SEC=UNCLASSIFIED]

Jennifer Burnett to: coh
Cc: Trisha Garrett, Peter Bird
Bcc: Xiangting Zhou

13/06/2013 01:54 PM

Dear Ms Oh,

Further to the TGA email of 22 April 2013 (sent by Trisha Garrett, Head OCM), I can now inform you that review of the availability of sodium fluoride as an active ingredient in listed medicines has been completed.

The TGA has determined that the current availability of this ingredient should be changed to provide consistency with the current scheduling of the substance in the *Standard for the Uniform Scheduling of Medicines and Poisons Number 3*. To enable this to occur, a new listing notice will be drafted and the existing notice revoked. This process should be completed within the original 60 day period proposed in our earlier email, but I will inform you if any delays are experienced.

Please contact me if you have any questions in the meantime.

regards,
Jenny

Jenny Burnett
Director
Pre-market Assessment Section
Office of Complementary Medicines

Phone: 02 6232 8280

Fax: 02 6203 1657

Email: jennifer.burnett@tga.gov.au

Therapeutic Goods Administration
PO Box 100
Woden ACT 2606
www.tga.gov.au

